monoclonal antibodies Archives
Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva
Sep. 28, 2023—A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.
Sep. 13, 2023—Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.
Oct. 6, 2022—Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.
Aug. 24, 2022—A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.
Mar. 3, 2022—Two years ago this week, the cataclysmic coronavirus known as SARS-CoV-2 arrived in Middle Tennessee.
Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
Dec. 2, 2021— by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...
Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases.
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.